Welcome to the WCN 2023 Interactive Program
Session Description:
Join us as we discuss patient assessment and the evolving treatment landscape in generalized myasthenia gravis (gMG). gMG is a rare but debilitating disease in which pathogenic immunoglobulin G (IgG) autoantibodies impair signal transmission at the neuromuscular junction, resulting in muscle weakness. The neonatal Fc receptor (FcRn) is a molecule that recycles IgG antibodies, including pathogenic autoantibodies, rescuing them from lysosomal degradation and perpetuating the underlying pathophysiology behind gMG. Experts will discuss the role of FcRn inhibition and present long-term clinical data for efgartigimod, an FcRn antagonist, in the treatment of patients with gMG. Experts will discuss patient outcomes and share their practical clinical experience with efgartigimod treatment.
*A limited number of lunch boxes will be provided
Session Description:
In this interactive and educational symposium, Dr Sharon Cohen (chair), Professor Sven Haller and Dr Ronan Factora will discuss the best practices for the diagnostic work-up of Alzheimer’s disease and strategies for coordinated care to optimize patient outcomes. The expert faculty will examine the importance of timely and accurate diagnosis of Alzheimer’s disease and provide practical insights into the latest strategies to help meet this goal. The panel will also discuss how a collaborative approach to care can optimize patient outcomes.
Each session will include interactive audience polling, a patient case study and audience Q&As to ensure ample engagement with the faculty.
This CME-accredited symposium is funded by an independent medical education grant from Eli Lilly and Company, and is jointly provided by USF Health and touchIME. This session is not included in the main event CME/CPD credit.
*A limited number of lunch boxes will be provided
Session Description:
Research has shown that the manner in which a diagnosis of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) is delivered is a source of discontent for many people living with the disease, their families, and their caregivers.
This is not surprising given that conveying sensitive news to patients is an arduous and emotionally challenging task for healthcare professionals (HCPs), which many feel ill-prepared for given the lack of medical training curricula devoted to this area.
How to Break the News in ALS/MND: A Primer for Physicians and Allied Health Professionals has been designed to improve HCP comfort and confidence in this task by providing them with the skills required to deliver challenging news effectively. The program centers around the A–L S–PIKES protocol which uses well-established principles of communication and counseling that are aimed at improving patient quality of life and promoting the well-being of HCPs involved in the care and management of people living with ALS/MND.
*A limited number of lunch boxes will be provided
Session Description:
This symposium will provide an overview of developmental and epileptic encephalopathies (DEEs), with a specific focus on Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex; key factors that aid the correct diagnosis of these conditions in paediatric, adolescent and adult patients will be discussed. Speakers will highlight the substantial burden that DEEs place on patients and their caregivers, and explore how management strategies can help to address both seizure- and non-seizure-related outcomes.
This meeting is organised and funded by Jazz Pharmaceuticals and is only intended for healthcare professionals attending the XXVI World Congress of Neurology (WCN 2023). Jazz Pharmaceuticals’ product(s) will be discussed in line with the EU Marketing Authorisation. Product(s) discussed may not be registered in all countries. Prescribing information may vary per country. Healthcare professionals must refer to their local prescribing information.
The session is not included in main event CME/CPD credit.
INT-NEU-2300025 | August 2023
*A limited number of lunch boxes will be provided
Session Description:
Myasthenia gravis is a chronic, autoimmune disorder that affects the function of the neuromuscular junction, leading to fluctuating, unpredictable symptoms that impact daily life. Treatment of myasthenia gravis has traditionally focused on symptomatic management; however, many of these symptomatic treatments are associated with toxicity and have a delayed onset of effect. The development of targeted therapies that address the underlying pathophysiology of the disorder has the potential to transform management and improve long-term outcomes. In this session, we will provide an overview of myasthenia gravis pathophysiology and the associated burden of current treatments; evaluate developments in the treatment of myasthenia gravis; and describe the impact that these new, targeted therapies have on patient outcomes.